AbbVie today announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week (DDW) Annual Meeting, May 2-5 in Chicago. AbbVie will present 18 abstracts, ...

Oruka Therapeutics’ long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, leading Jefferies analysts to predict the asset could beat out AbbVie’s Skyrizi ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Johnson & Johnson said the FDA has approved its once-daily psoriasis pill Icotyde. Icotyde targets IL-23, rivaling best-selling shots Tremfya and Skyrizi. J&J hasn't announced how much Icotyde will ...

AbbVie (ABBV) fell ~4% on Wednesday as BNP Paribas argued that its immunology blockbuster Skyrizi could face competition from Icotyde, a newly approved plaque psoriasis pill developed by Johnson & ...

Blue sneakers, water and apple on black background. Concept of healthy lifestile and food, everyday training and force of will. Fatigue is different from simply being tired. When you’re tired, you can ...

AbbVie ABBV reported 9% revenue growth in 2025 and provided 2026 guidance of $67 billion in revenue (10% growth) and a 150-basis-point improvement in adjusted operating margin. Shares fell 4% in ...

Skyrizi is used to treat autoimmune and inflammatory conditions like Crohn’s disease and plaque psoriasis. It is administered via intravenous injection by a healthcare professional or subcutaneous ...

Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...